Related Experiment Video
Updated: Jan 26, 2026

Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers
Published on: July 21, 2017
Self-assembled multicomponent prodrugs with GSH/ROS site-responsiveness enable spatiotemporally controlled release
Chaozheng Zhang1, Yao Chen2, Xiaoke Shi3
1State Key Laboratory of Southwestern Chinese Medicine Resources, Institute of Herbgenomics, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China; Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Abstract:
The resistance of non-small cell lung cancer (NSCLC) to Paclitaxel (PTX) stems from the enhanced drug efflux mediated by ATP-binding cassette (ABC) transporters and the upregulated PARP1-dependent DNA repair pathway. To address this challenge, the present study constructed a self-assembled nanoprodrug, PSOTNs, featuring covalent conjugation of three therapeutic agents. Structurally, PTX was functionalized with a disulfide bond to confer GSH-responsive release, whereas Olaparib (OLP) was tethered via a thioketal linker for ROS-triggered liberation, and tetramethylpyrazine (TMP) was hydrophobically modified to drive self-assembly and facilitated mitochondria-specific targeting under acidic conditions. The delicate PSOTNs exhibited high drug loading, favorable colloidal stability, and enhanced tumor accumulation via the EPR effect. Upon cellular internalization, the elevated GSH level prompted rapid release of PTX, effectively inhibiting microtubule dynamics. Concurrently, TMP-mediated mitochondrial enrichment and the subsequent ROS-triggered cleavage released OLP along with cinnamaldehyde, which synergistically amplified oxidative stress, induced mitochondrial dysfunction, and suppressed P-glycoprotein-mediated drug efflux. In vitro assays demonstrated that PSOTNs significantly enhanced drug accumulation, induced DNA damage, provoked G2/M cell cycle arrest, and promoted apoptosis, outperforming both individual agents and the non-responsive control. Furthermore, PSOTNs revealed potent tumor growth inhibition in A549/Tax xenograft models, prolonged systemic circulation, and excellent biocompatibility. In summary, PSOTNs represent a novel nanotherapeutic strategy that overcomes PTX resistance through a triple synergistic mechanism of "microtubule disruption-DNA repair inhibition-mitochondrial function intervention," offering a promising paradigm for the treatment of drug-resistant malignancies.
Insights
This study developed PSOTNs, a novel nanoprodrug, to overcome Paclitaxel resistance in non-small cell lung cancer (NSCLC). PSOTNs combine three drugs for synergistic effects, enhancing treatment efficacy against resistant tumors.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Non-small cell lung cancer (NSCLC) often develops resistance to Paclitaxel (PTX).
- Mechanisms of resistance include enhanced drug efflux via ATP-binding cassette (ABC) transporters and upregulated PARP1-dependent DNA repair.
- Novel strategies are needed to overcome PTX resistance in NSCLC.
Purpose of the Study:
- To construct and evaluate a self-assembled nanoprodrug (PSOTNs) for overcoming PTX resistance in NSCLC.
- To investigate the synergistic therapeutic effects of combining PTX, Olaparib (OLP), and tetramethylpyrazine (TMP) within a nanocarrier.
- To explore the multi-pronged drug release mechanism triggered by intracellular stimuli (GSH, ROS, acidic pH).
Main Methods:
- Covalent conjugation of PTX (disulfide bond), OLP (thioketal linker), and TMP (hydrophobic modification) into PSOTNs.
- Characterization of PSOTNs for drug loading, colloidal stability, and tumor accumulation (EPR effect).
- In vitro evaluation of drug release, cellular uptake, DNA damage, cell cycle arrest, apoptosis, and P-glycoprotein inhibition.
- In vivo assessment of tumor growth inhibition in A549/Tax xenograft models and biocompatibility studies.
Main Results:
- PSOTNs demonstrated high drug loading, stability, and tumor accumulation.
- Stimuli-responsive release of PTX and OLP occurred intracellularly, leading to microtubule disruption and DNA repair inhibition.
- TMP facilitated mitochondria-specific targeting, amplifying oxidative stress and suppressing drug efflux.
- PSOTNs significantly enhanced drug accumulation, induced DNA damage, G2/M arrest, and apoptosis in vitro.
- PSOTNs showed potent tumor growth inhibition, prolonged circulation, and good biocompatibility in vivo.
Conclusions:
- PSOTNs represent a novel nanotherapeutic strategy overcoming PTX resistance in NSCLC.
- The triple synergistic mechanism involves microtubule disruption, DNA repair inhibition, and mitochondrial function intervention.
- PSOTNs offer a promising paradigm for treating drug-resistant malignancies.
Related Concept Videos
Prodrugs
Prodrugs help overcome...
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Resistivity
Resistance
Responses to Drought and Flooding
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...

